Ken Griffin Castle Biosciences Inc Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Castle Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 56,000 shares of CSTL stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,000
Previous 12,400
351.61%
Holding current value
$1.59 Million
Previous $269,000
493.68%
% of portfolio
0.0%
Previous 0.0%
Shares
21 transactions
Others Institutions Holding CSTL
# of Institutions
202Shares Held
26MCall Options Held
303KPut Options Held
30.3K-
Black Rock Inc. New York, NY3.04MShares$86.6 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT1.83MShares$52 Million0.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.75MShares$49.8 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.54MShares$43.8 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.26MShares$35.9 Million0.61% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $748M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...